IP Library Granted Patent US 7,063,836
Granted Patent B2
US 7,063,836 · App. 10/288,487 · Granted Jun 20, 2006

Compositions and methods for inhibiting pathogenic growth

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,063,836
App. No.
10/288,487
Granted
Jun 20, 2006
Kind
B2
Abstract

The invention includes methods and compositions for treating an animal to inhibit the incidence and growth of E. coli O157:H7 and other pathogenic bacteria. The treatment method comprises administering a therapeutically effective amount of Lactobacillus acidophilus or one or a combination of a number of other probiotic bacteria to an animal. An alternative treatment method comprises administering a therapeutically effective amount of a lactic acid producing bacterium such as Lactobacillus acidophilus in combination with a lactate utilizing bacterium such as Propionibacterium freudenreichii.

Claims (8)

1. A method of treating an intestinal pathogenic infection in a ruminant caused by a pathogenic bacterium, the method comprising:

administering to the ruminant a composition comprising a therapeutically effective amount of a lactic acid producing bacterium, wherein lactic acid producing bacterium is Lactobacillus acidophilus strain selected from the strains C28, M35, LA51 and L411 that inhibits the growth of the pathogenic bacterium in the ruminant; and a lactate utilizing bacterium, wherein the lactate utilizing bacterium is Propionibacterium freudenreichil strain selected from the strains P9, PF24 and P42;

thereby reducing the quantity of the pathogenic bacterium in the intestine of the ruminant.

2. The method of claim 1 , wherein the Lactobacillus acidophilus is the LA51 strain.

3. The method of claim 1 , wherein the lactate utilizing bacterium and the lactic acid producing bacterium are each administered in an amount of greater than 1×10 8 CFU/day.

4. The method of claim 1 , wherein the lactate utilizing bacterium and the lactic acid producing bacterium are each administered in an amount of greater than 1×10 9 CFU/day.

5. The method of claim 1 , wherein the pathogen is selected from the group consisting of Escherichia coli, Salmonella spp., and Staphylococcus aureus.

6. The method of claim 1 , wherein the pathogen is Escherichia coil O157:H7.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2016
From: NUTRITION PHYSIOLOGY COMPANY, LLC
To: CHR. HANSEN A/S
Reel/Frame 038287/0072 →
SECURITY AGREEMENT Recorded Jul 19, 2012
From: NUTRITION PHYSIOLOGY COMPANY, LLC
To: FIFTH THIRD BANK
Reel/Frame 028597/0811 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2008
From: NUTRITION PHYSIOLOGY CORPORATION
To: NUTRITION PHYSIOLOGY COMPANY, LLC
Reel/Frame 021603/0775 →
SECURITY AGREEMENT Recorded Sep 22, 2008
From: NUTRITION PHYSIOLOGY COMPANY, LLC
To: MADISON CAPITAL FUNDING LLC, AS AGENT
Reel/Frame 021561/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2006
From: WARE, DOUGLAS R.; GARNER, BRYAN
To: NUTRITION PHYSIOLOGY CORPORATION
Reel/Frame 017376/0279 →
Continuity (4)
Continuation 1027314100 · Oct 18, 2002
Provisional Application 6031905400 · Jan 8, 2002
Provisional Application 6031958700 · Oct 1, 2002
Related Publication 20030175306A1 · Sep 18, 2003